Source-grounded facts extracted from Indaptus Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Walt A. Linscott resigned as Chief Operating Officer at Indaptus Therapeutics, Inc..
“Effective as of June 1, 2026, Mr. Walt A. Linscott, Esq. resigned as the Chief Operating Officer of the Company, and, pursuant to a consulting agreement with the Company dated June 1, 2026, will serve as a consultant for the Company.”
Avraham Ben-Tzvi resigned as Director at Indaptus Therapeutics, Inc..
“Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).”
David E. Lazar resigned as Director at Indaptus Therapeutics, Inc..
“Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Company ”).”
Indaptus Therapeutics, Inc. underwent a change of control involving Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng for $11,200,000 (closed 2026-03-23).
“on March 23, 2026, David Lazar sold, in accordance with the rights afforded to Mr. Lazar in the Purchase Agreement, all of his interest and rights in the 700,000 shares of Series AAA Preferred Stock and all of his interest and rights to 196,800 shares of Series AA Preferred Stock to Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng (the “Purchasers”) in certain percentages set forth in the definitive agreements related to such transaction, for an aggregate purchase price of $11,200,000 (the “Purchase Price”).”
Indaptus Therapeutics, Inc. issued common stock.
“the Reverse Stock Split, once implemented, will result in a reduction in the number of shares of common stock outstanding and may affect certain rights of security holders, including voting rights and the number of shares available for future issuance.”
Indaptus Therapeutics, Inc.: Amended Section 2.13 of the Bylaws to provide that stockholder action must be at a meeting and not by written consent, unless the Certificate of Incorporation provides otherwise (effective 2026-02-27).
“upon filing of the Certificate of Amendment with the Secretary of State of Delaware, Section 2.13 of the Company’s Amended and Restated Bylaws shall be deemed to be amended as follows: “Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.””
Indaptus Therapeutics, Inc.: Approved amendments to the Charter to increase authorized common stock to 1,000,000,000 shares and permit stockholder action by written consent (effective 2026-02-27).
“stockholders of the Company approved amendments to the Company’s Charter to (i) increase the number of authorized shares of our common stock to 1,000,000,000 (one billion) shares, and (ii) permit stockholder approval by written consent in lieu of a meeting.”
Indaptus Therapeutics, Inc. underwent a change of control involving David E. Lazar (closed 2026-02-26).
“greement (the “Purchase Agreement”) with David E. Lazar (“Mr. Lazar”) pursuant to which he purchased from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series”
Indaptus Therapeutics, Inc. entered into Repricing Agreements with Executing Holders (effective 2026-02-11).
“On February 11, 2026, Indaptus Therapeutics, Inc. (the “Company”) entered into warrant repricing agreements (the “Repricing Agreements”) with certain holders (the “Executing Holders”) of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60 (the “Executing Warrants”).”
Indaptus Therapeutics, Inc. entered into Purchase Agreement with David E. Lazar valued at $6.0 million (effective 2025-12-22).
“On December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Preferred Stock, the “Preferred Stock”) of the Company at a purchase price of $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million”
Indaptus Therapeutics, Inc. issued 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock of preferred stock to David E. Lazar for $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million.
“on December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Preferred Stock, the “Preferred Stock”) of the Company at a purchase price of $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million”
Indaptus Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock (effective 2025-06-26).
“on June 26, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split, which became effective as of 5:00 p.m. Eastern Time on June 26, 2025.”
Indaptus Therapeutics, Inc. incurred convertible notes of aggregate principal amount of $2.3 million with certain accredited investors at 6% per year maturing July 28, 2026.
“the offering in a private placement of convertible promissory notes in the aggregate principal amount of $2.3 million (the "Notes") and warrants (the "Warrants") to purchase shares of common stock, par value $0.01 per share ("Common Stock"). The closing of private placement occurred on June 12, 2025”
Indaptus Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 31, 2025, Indaptus Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busi”
Indaptus Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 31, 2025, Indaptus Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements”
Indaptus Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 8, 2024, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Indaptus Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination procedures, add exclusive forum provision, and make technical changes (effective 2024-01-22).
“On January 22, 2024, the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.”
Indaptus Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: EPS approximately $0.47.
“On November 6, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Indaptus Therapeutics, Inc. reported second quarter ended June 30, 2023 results: EPS Loss per share for the three months ended June 30, 2023 was approximately $0.39.
“Loss per share for the three months ended June 30, 2023 was approximately $0.39”
Indaptus Therapeutics, Inc. shareholders approved Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.
“Proposal 2. Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Indaptus Therapeutics, Inc. shareholders approved Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal. at the 2023-05-25 meeting.
“Proposal 1 . Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal.”
Indaptus Therapeutics, Inc. reported first quarter ended March 31, 2023 results: EPS approximately $0.51.
“Loss per share for the three-month period ended March 31, 2023 was approximately $0.51 compared with approximately $0.41 for the three-month period ended March 31, 2022.”
Walt A. Linscott was appointed as Chief Operating Officer at Indaptus Therapeutics, Inc..
“On March 22, 2023, the Board appointed Walt A. Linscott, the Company's Chief Business Officer, as the Company's Chief Operating Officer, effective immediately.”
Indaptus Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On March 17, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Robert Martell was appointed as Class I director at Indaptus Therapeutics, Inc..
“On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.”
Indaptus Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at Up to $20,000,000 (effective 2022-12-22).
“On December, 22, 2022, Indaptus Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $20.0 million of the Company’s common stock, $0.01 par value per share.”
Indaptus Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 10, 2022, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2022.”
Nir Sassi was appointed as Chief Financial Officer at Indaptus Therapeutics, Inc..
“On February 1, 2022, Intec Pharma Ltd. (“Intec”), a wholly owned subsidiary of Indaptus Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Employment Agreement”) with Nir Sassi, the Company’s Chief Financial Officer.”
Mark J. Gilbert was elected as Director at Indaptus Therapeutics, Inc..
“On the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately.”
Hoonmo Lee resigned as Director at Indaptus Therapeutics, Inc..
“On November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”), and from all committees of the Board.”
Michael Newman was appointed as Chief Scientific Officer at Indaptus Therapeutics, Inc..
“Michael Newman, Ph.D. was appointed as Chief Scientific Officer.”
Brian O’Callaghan was appointed as Director at Indaptus Therapeutics, Inc..
“each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.”
Hoonmo Lee was appointed as Director at Indaptus Therapeutics, Inc..
“each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.”
Michael Newman was appointed as Director at Indaptus Therapeutics, Inc..
“each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.”
Walt Linscott was appointed as Chief Business Officer at Indaptus Therapeutics, Inc..
“Walt Linscott Chief Business Officer”
Nir Sassi was appointed as Chief Financial Officer at Indaptus Therapeutics, Inc..
“Nir Sassi Chief Financial Officer”
Jeffrey Meckler was appointed as Chief Executive Officer at Indaptus Therapeutics, Inc..
“Jeffrey Meckler Chief Executive Officer”
Dr. Roger J. Pomerantz was appointed as Chairman at Indaptus Therapeutics, Inc..
“Dr. Roger J. Pomerantz also was appointed as Chairman of the Company’s board of directors.”
Dr. Roger J. Pomerantz was appointed as Director at Indaptus Therapeutics, Inc..
“each of Hila Karah, Anthony J. Maddauluna, William B. Hayes and Dr. Roger J. Pomerantz was appointed as a director of Intec Parent, Inc.”
William B. Hayes was appointed as Director at Indaptus Therapeutics, Inc..
“each of Hila Karah, Anthony J. Maddauluna, William B. Hayes and Dr. Roger J. Pomerantz was appointed as a director of Intec Parent, Inc.”
Anthony J. Maddaluna was appointed as Director at Indaptus Therapeutics, Inc..
“each of Hila Karah, Anthony J. Maddauluna, William B. Hayes and Dr. Roger J. Pomerantz was appointed as a director of Intec Parent, Inc.”
Hila Karah was appointed as Director at Indaptus Therapeutics, Inc..
“each of Hila Karah, Anthony J. Maddauluna, William B. Hayes and Dr. Roger J. Pomerantz was appointed as a director of Intec Parent, Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.